The Burden and Determinants of Emerging and Re-emerging Fungal Pathogens: Resistance to Antifungal Drugs, Mechanisms, and Future Mitigation Strategies

Abayeneh  Girma

Abayeneh Girma Department of Biology, College of Natural and Computational Science, Mekdela Amba University, Tuluawlia, Ethiopia.

Keywords: Fungal Pathogens, Antifungal Drug Resistance, Antifungal Drug Tolerance, Invasive Fungal Infections, Immunocompromised Patients, Resistance Detection

Abstract

Emerging and re-emerging human fungal pathogens are becoming more closely associated, with 13,000,000 morbidity and 1500000 mortality incidences per year. Human fungal pathogens are mainly found in critically ill and immunocompromised patients. Climate change, agricultural activities, occupational hazards, deforestation, migratory trends of people, clay dispersion, decreased immunity of patients, biofilm development, medication tolerance, and resistance to antifungal therapies are all factors that contribute to the emergence of fungal
diseases. This document makes recommendations for those who set policy, general population health experts, and other respective bodies to improve the laboratory infrastructure and monitoring, promote innovative and affordable investigations, and execute public health programmes to combat these fungal infections, including preventing the emergence of antifungal medication resistance.

How to cite this article:
Girma A. Burden and Determinants of Emergingand Re-emerging Fungal Pathogens: Resistance to Antifungal Drugs, Mechanisms, and Future Mitigation Strategies. J Commun Dis. 2023;55(4):86-96.

DOI: https://doi.org/10.24321/0019.5138.202360

References

Garvey M, Meade E, Rowan NJ. Effectiveness of front line and emerging fungal disease prevention and

control interventions and opportunities to address appropriate eco-sustainable solutions. Sci Total Environ. 2022;851(Pt 2):158284. [PubMed] [Google Scholar]

Rayens E, Norris KA. Prevalence and healthcare burden of fungal infections in the United States, 2018. Open

Forum Infect Dis. 2022;9(1):ofab593. [PubMed] [Google Scholar]

Su H, Han L, Huang X. Potential targets for the development of new antifungal drugs. J Antibiot. 2018;71(12):978-91. [PubMed] [Google Scholar]

Garvey M, Rowan NJ. Pathogenic drug resistant fungi: a review of mitigation strategies. Int J Mol Sci.

;24(2):1584. [PubMed] [Google Scholar]

Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases—

estimate precision. J Fungi (Basel). 2017;3(4):57. [PubMed] [Google Scholar]

Huang J, Liu C, Zheng X. Clinical features of invasive fungal disease in children with no underlying disease.

Sci Rep. 2022;12(1):208. [PubMed] [Google Scholar]

Alastruey-Izquierdo A, Melhem MS, Bonfietti LX, Rodriguez-Tudela JL. Susceptibility test for fungi: clinical

and laboratorial correlations in medical mycology. Rev Inst Med Trop São Paulo. 2015;57(Suppl 19):57-64.

[PubMed] [Google Scholar]

Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci

Transl Med. 2012;4(165):165rv13. [PubMed] [Google Scholar]

Firacative C. Invasive fungal disease in humans: are we aware of the real impact? Mem Inst Oswaldo Cruz.

;115:e200430. [PubMed] [Google Scholar]

Koehler P, Bassetti M, Kochanek M, ShimabukuroVornhagen A, Cornely OA. Intensive care management of influenza-associated pulmonary aspergillosis. Clin Microbiol Infect. 2019;25(12):1501-9. [PubMed]

[Google Scholar]

Xu L, Chen B, Wang F, Wei C, Liu H, Liu J, Herth FJ, Luo F. A higher rate of pulmonary fungal infection in chronic

obstructive pulmonary disease patients with influenza in a large tertiary hospital. Respiration. 2019;98(5):391-

[PubMed] [Google Scholar]

Schauwvlieghe AF, Rijnders BJ, Philips N, Verwijs R, Vanderbeke L, Tienen CV, Lagrou K, Verweij PE, Veerdonk FL, Gommers D, Spronk P, Bergmans DC, Hoedemakers A, Andrinopoulou ER, Berg CH, Juffermans NP, Hodiamont CJ, Vonk AG, Depuydt P, Boelens J, Wauters J; Dutch-Belgian Mycosis Study Group. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782-92. [PubMed] [Google Scholar]

Huang L, Zhang N, Huang X, Xiong S, Feng Y, Zhang Y, Li M, Zhan Q. Invasive pulmonary aspergillosis in patients with influenza infection: a retrospective study and review of the literature. Clin Respir J. 2019;13(4):202-11. [PubMed] [Google Scholar]

Salehi M, Ahmadikia K, Badali H, Khodavaisy S. Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran. Mycopathologia. 2020;185(4):607-11. [PubMed] [Google Scholar]

Bhatt K, Agolli A, Patel MH, Garimella R, Devi M, Garcia E, Amin H, Domingue C, Castillo RG, Sanchez-Gonzalez

M. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries

(Craiova). 2021;9(1):e126. [PubMed] [Google Scholar]

Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: we

should be prepared. J Mycol Med. 2020;30(2):100971. [PubMed] [Google Scholar]

Ekeng BE, Davies AA, Osaigbovo II, Warris A, Oladele RO, Denning DW. Pulmonary and extrapulmonary

manifestations of fungal infections misdiagnosed as tuberculosis: the need for prompt diagnosis and

management. J Fungi (Basel). 2022;8(5):460. [PubMed] [Google Scholar]

Osman NM, Gomaa AA, Sayed NM, Abed-el-aziz AA. Microarray detection of fungal infection in pulmonary

tuberculosis. Egypt J Chest Dis Tuberc. 2013;62(1):151- 7. [Google Scholar]

Njovu IK, Musinguzi B, Mwesigye J, Kassaza K, Turigurwa J, Nuwagira E, Bazira J, Kabanda T, Mpeirwe M, Ampaire L, Mutekanga A, Kiguli J, Achan B, Itabangi H. Status of pulmonary fungal pathogens among individuals with clinical features of pulmonary tuberculosis at Mbarara University Teaching Hospital in Southwestern Uganda. Ther Adv Infect Dis. 2021;8:20499361211042477. [PubMed] [Google Scholar]

Steffan B, Hoselton SA, Schuh JM. Fungal asthma and disease severity with Pseudomonas aeruginosa coinfection. Proc North Dakota Acad Sci. 2017;71:44-5. [Google Scholar]

Kozik AJ, Huang YJ. The microbiome in asthma: role in pathogenesis, phenotype, and response to treatment.

Ann Allergy Asthma Immunol. 2019;122(3):270-5. [PubMed] [Google Scholar]

Gravito-Soares M, Gravito-Soares E, Lopes S, Ribeiro G, Figueiredo P. Spontaneous fungal peritonitis: a

rare but severe complication of liver cirrhosis. Eur J Gastroenterol Hepatol. 2017;29(9):1010-6. [PubMed]

[Google Scholar]

Alexopoulou A, Vasilieva L, Agiasotelli D, Dourakis SP. Fungal infections in patients with cirrhosis. J Hepatol.

;63(4):1043-5. [PubMed] [Google Scholar]

Fernández J, Piano S, Bartoletti M, Wey EQ. Management of bacterial and fungal infections in cirrhosis: the

MDRO challenge. J Hepatol. 2021;75(Suppl 1):S101-17. [PubMed] [Google Scholar]

Madney Y, Shalaby L, Hammad M, Elanany M, Hassan R, Youssef A, Abdo I, Zaki A, Khedr R. COVID-19-associated pulmonary fungal infection among pediatric cancer patients, a single center experience. J Fungi (Basel). 2022;8(8):850. [PubMed] [Google Scholar]

Aparajay P, Dev A. Functionalized niosomes as a smart delivery device in cancer and fungal infection. Eur

J Pharm Sci. 2022;168:106052. [PubMed] [Google Scholar]